{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:46:10Z","timestamp":1794584770919,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bando per la valorizzazione della Ricerca Istituzionale in ambito oncologico 2019","award":["BRI_2019"],"award-info":[{"award-number":["BRI_2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of MPM is marked by a progressive transdifferentiation that converts well differentiated epithelioid (E) cells into undifferentiated and pleomorphic sarcomatoid (S) phenotypes. Catching the way this transition takes place is necessary to understand how MPM develops and progresses and it is mandatory to improve patients\u2019 management and life expectancy. Bulk transcriptomic approaches, while providing a significant overview, failed to resolve the timing of this evolution and to identify the hierarchy of molecular events through which this transition takes place.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We applied a spatially resolved, high-dimensional transcriptomic approach to study MPM morphological evolution. 139 regions across 8 biphasic MPMs (B-MPMs) were profiled using the GeoMx\u2122Digital Spatial Profiler to reconstruct the positional context of transcriptional activities and the spatial topology of MPM cells interactions. Validation was conducted on an independent large cohort of 84 MPMs by targeted digital barcoding analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results demonstrated the existence of a complex circular ecosystem in which, within a strong asbestos-driven inflammatory environment, MPM and immune cells affect each other to support S-transdifferentiation. We also showed that TGFB1 polarized M2-Tumor Associated Macrophages foster immune evasion and that TGFB1 expression correlates with reduced survival probability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Besides providing crucial insights into the multidimensional interactions governing MPM clinical evolution, these results open new perspectives to improve the use of immunotherapy in this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-023-01816-9","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T01:01:31Z","timestamp":1689555691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"F","family":"Torricelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Manicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lococo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciarrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207\u201318.","journal-title":"N Engl J Med"},{"key":"1816_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1816_CR3","doi-asserted-by":"crossref","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. 2019, 10:1333.","DOI":"10.1038\/s41467-019-09307-6"},{"key":"1816_CR4","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA. Integrative molecular characterization of malignant pleural mesothelioma. 2018, 8:1548\u201365."},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"1816_CR6","doi-asserted-by":"crossref","unstructured":"Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N. Deep learning-based classification of mesothelioma improves prediction of patient outcome. 2019, 25:1519\u201325.","DOI":"10.1038\/s41591-019-0583-3"},{"key":"1816_CR7","doi-asserted-by":"crossref","unstructured":"Mangiante L, Alcala N. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. 2023, 55:607\u201318.","DOI":"10.1038\/s41588-023-01321-1"},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","volume":"15","author":"F Galateau Salle","year":"2020","unstructured":"Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, et al. Comprehensive Molecular and pathologic evaluation of Transitional Mesothelioma assisted by Deep Learning Approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. J Thorac Oncol. 2020;15:1037\u201353.","journal-title":"J Thorac Oncol"},{"key":"1816_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","volume":"13","author":"F Galateau Salle","year":"2018","unstructured":"Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, et al. New Insights on Diagnostic reproducibility of Biphasic Mesotheliomas: a multi-institutional evaluation by the International Mesothelioma Panel from the MESOPATH Reference Center. J Thorac Oncol. 2018;13:1189\u2013203.","journal-title":"J Thorac Oncol"},{"key":"1816_CR10","unstructured":"International Agency for Research on Cancer; WHO Classification of Tumours Editorial Board. Thoracic tumours.: 2021. WHO classification of tumours series, 5th ed.; vol.\u00a05. https:\/\/publications.iarc.fr\/595."},{"key":"1816_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1816_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/modpathol.2011.144","volume":"25","author":"A Fassina","year":"2012","unstructured":"Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, Fassan M. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25:86\u201399.","journal-title":"Mod Pathol"},{"key":"1816_CR13","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"A de Reyni\u00e8s","year":"2014","unstructured":"de Reyni\u00e8s A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sall\u00e9 F, Copin MC, Hofman P, Cazes A, et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res. 2014;20:1323\u201334.","journal-title":"Clin Cancer Res"},{"key":"1816_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","volume":"18","author":"V Marx","year":"2021","unstructured":"Marx V. Method of the year: spatially resolved transcriptomics. Nat Methods. 2021;18:9\u201314.","journal-title":"Nat Methods"},{"key":"1816_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/1078-0432.CCR-19-2356","volume":"26","author":"S Luminari","year":"2020","unstructured":"Luminari S, Donati B, Casali M, Valli R, Santi R, Puccini B, Kovalchuk S, Ruffini A, Fama A, Berti V, et al. A gene expression-based Model to predict metabolic response after two Courses of ABVD in Hodgkin Lymphoma Patients. Clin Cancer Res. 2020;26:373\u201383.","journal-title":"Clin Cancer Res"},{"key":"1816_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-18-2364","volume":"25","author":"G Manzotti","year":"2019","unstructured":"Manzotti G, Torricelli F, Benedetta D, Lococo F, Sancisi V, Rossi G, Piana S, Ciarrocchi A. An epithelial-to-Mesenchymal Transcriptional switch triggers evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and identifies Dasatinib as New Therapeutic option. Clin Cancer Res. 2019;25:2348\u201360.","journal-title":"Clin Cancer Res"},{"key":"1816_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and Consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity"},{"key":"1816_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19:402\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"1816_CR19","doi-asserted-by":"crossref","unstructured":"Mantovani A, Allavena P, Marchesi F. Macrophages as tools and targets in cancer therapy. 2022, 21:799\u2013820.","DOI":"10.1038\/s41573-022-00520-5"},{"key":"1816_CR20","doi-asserted-by":"crossref","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. 2023, 23:238\u201357.","DOI":"10.1038\/s41568-022-00547-1"},{"key":"1816_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14\u201320.","journal-title":"Immunity"},{"key":"1816_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell"},{"key":"1816_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/JTO.0b013e31820ce2c7","volume":"6","author":"SC Kao","year":"2011","unstructured":"Kao SC, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011;6:602\u20135.","journal-title":"J Thorac Oncol"},{"key":"1816_CR24","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/cncr.23034","volume":"110","author":"L Greillier","year":"2007","unstructured":"Greillier L, Cavailles A, Fraticelli A, Scherpereel A, Barlesi F, Tassi G, Thomas P, Astoul P. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer. 2007;110:2248\u201352.","journal-title":"Cancer"},{"key":"1816_CR25","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.athoracsur.2004.05.007","volume":"78","author":"R Bueno","year":"2004","unstructured":"Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78:1774\u20136.","journal-title":"Ann Thorac Surg"},{"key":"1816_CR26","doi-asserted-by":"crossref","unstructured":"Larsson L, Fris\u00e9n J, Lundeberg J. Spatially resolved transcriptomics adds a new dimension to genomics. 2021, 18:15\u20138.","DOI":"10.1038\/s41592-020-01038-7"},{"key":"1816_CR27","doi-asserted-by":"crossref","unstructured":"Winkler J, Abisoye-Ogunniyan A. Concepts of extracellular matrix remodelling in tumour progression and metastasis. 2020, 11:5120.","DOI":"10.1038\/s41467-020-18794-x"},{"key":"1816_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786\u2013801.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1816_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.niox.2021.08.004","volume":"116","author":"J Zhu","year":"2021","unstructured":"Zhu J, Yang G. H(2)S signaling and extracellular matrix remodeling in cardiovascular diseases: a tale of tense relationship. Nitric Oxide. 2021;116:14\u201326.","journal-title":"Nitric Oxide"},{"key":"1816_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.freeradbiomed.2015.05.002","volume":"86","author":"SH Chew","year":"2015","unstructured":"Chew SH, Toyokuni S. Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic Biol Med. 2015;86:166\u201378.","journal-title":"Free Radic Biol Med"},{"key":"1816_CR31","doi-asserted-by":"crossref","unstructured":"Fendt SM, Frezza C. Targeting metabolic plasticity and Flexibility Dynamics for Cancer Therapy. 2020, 10:1797\u2013807.","DOI":"10.1158\/2159-8290.CD-20-0844"},{"key":"1816_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nmat4009","volume":"13","author":"O Chaudhuri","year":"2014","unstructured":"Chaudhuri O, Koshy ST, Branco da Cunha C, Shin JW, Verbeke CS, Allison KH, Mooney DJ. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat Mater. 2014;13:970\u20138.","journal-title":"Nat Mater"},{"key":"1816_CR33","doi-asserted-by":"crossref","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. 2018, 9:4692.","DOI":"10.1038\/s41467-018-06654-8"},{"key":"1816_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","volume":"139","author":"P Stockhammer","year":"2020","unstructured":"Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer. 2020;139:124\u201332.","journal-title":"Lung Cancer"},{"key":"1816_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1816_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829\u2013842e813.","journal-title":"Cell"},{"key":"1816_CR37","doi-asserted-by":"publisher","first-page":"10649","DOI":"10.1073\/pnas.1605885113","volume":"113","author":"V Schuette","year":"2016","unstructured":"Schuette V, Embgenbroich M, Ulas T, Welz M, Schulte-Schrepping J, Draffehn AM, Quast T, Koch K, Nehring M, K\u00f6nig J, et al. Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4. Proc Natl Acad Sci U S A. 2016;113:10649\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1816_CR38","doi-asserted-by":"crossref","unstructured":"Horio D, Minami T. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma. 2020, 111:2895\u2013906.","DOI":"10.1111\/cas.14523"},{"key":"1816_CR39","doi-asserted-by":"publisher","first-page":"995651","DOI":"10.3389\/fonc.2022.995651","volume":"12","author":"K Yang","year":"2022","unstructured":"Yang K, Yang T, Yang T, Yuan Y, Li F. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. Front Oncol. 2022;12:995651.","journal-title":"Front Oncol"},{"key":"1816_CR40","doi-asserted-by":"publisher","first-page":"870352","DOI":"10.3389\/fonc.2022.870352","volume":"12","author":"H Ollila","year":"2022","unstructured":"Ollila H, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Paavolainen L, Paajanen J, V\u00e4lim\u00e4ki K, Sutinen E, Wolff H, R\u00e4s\u00e4nen J, Kallioniemi O, Myll\u00e4rniemi M, et al. Prognostic role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma. Front Oncol. 2022;12:870352.","journal-title":"Front Oncol"},{"key":"1816_CR41","doi-asserted-by":"crossref","unstructured":"Creaney J, Patch AM, Addala V, Sneddon SA, Nones K, Dick IM, Lee YCG, Newell F, Rouse EJ, Naeini MM et al. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. 2022, 14:58.","DOI":"10.1186\/s13073-022-01060-8"},{"key":"1816_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","volume":"11","author":"LA Lievense","year":"2016","unstructured":"Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J Thorac Oncol. 2016;11:1755\u201364.","journal-title":"J Thorac Oncol"},{"key":"1816_CR43","doi-asserted-by":"crossref","unstructured":"Magkouta SF, Vaitsi PC, Pappas AG, Iliopoulou M, Kosti CN, Psarra K, Kalomenidis IT. CSF1\/CSF1R Axis Blockade limits Mesothelioma and enhances efficiency of Anti-PDL1 immunotherapy. Cancers (Basel) 2021, 13.","DOI":"10.3390\/cancers13112546"},{"key":"1816_CR44","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, et al. Programmed death 1 Blockade with Nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569\u201376.","journal-title":"J Thorac Oncol"},{"key":"1816_CR45","doi-asserted-by":"crossref","unstructured":"Okada M, Kijima T. Clinical efficacy and safety of Nivolumab: results of a Multicenter, Open-label, Single-arm, japanese phase II study in malignant pleural mesothelioma (MERIT). 2019, 25:5485\u201392.","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"1816_CR46","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22:1530\u201340.","journal-title":"Lancet Oncol"},{"key":"1816_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"1816_CR48","doi-asserted-by":"publisher","first-page":"639","DOI":"10.21037\/tlcr-19-485","volume":"9","author":"NK Brockwell","year":"2020","unstructured":"Brockwell NK, Alamgeer M, Kumar B, Rivalland G, John T, Parker BS. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Transl Lung Cancer Res. 2020;9:639\u201345.","journal-title":"Transl Lung Cancer Res"},{"key":"1816_CR49","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.2147\/OTT.S317434","volume":"14","author":"D Liao","year":"2021","unstructured":"Liao D, Yu Y, Mei Q, Wang Z, Li X, Jia Y, Kong F. Advances in Immunotherapy of Malignant Pleural Mesothelioma. Onco Targets Ther. 2021;14:4477\u201384.","journal-title":"Onco Targets Ther"},{"key":"1816_CR50","doi-asserted-by":"publisher","first-page":"1121557","DOI":"10.3389\/fimmu.2023.1121557","volume":"14","author":"M Perrino","year":"2023","unstructured":"Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress. Front Immunol. 2023;14:1121557.","journal-title":"Front Immunol"},{"key":"1816_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.lungcan.2021.11.006","volume":"162","author":"AK Nowak","year":"2021","unstructured":"Nowak AK, Chin WL, Keam S, Cook A. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma. Lung Cancer. 2021;162:162\u20138.","journal-title":"Lung Cancer"},{"issue":"5","key":"1816_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399.","journal-title":"Ann Oncol"},{"issue":"3","key":"1816_CR53","doi-asserted-by":"publisher","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","volume":"5","author":"T Meirson","year":"2022","unstructured":"Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, et al. Comparison of 3 randomized clinical trials of Frontline Therapies for Malignant Pleural Mesothelioma. JAMA Netw Open. 2022;5(3):e221490.","journal-title":"JAMA Netw Open"},{"key":"1816_CR54","doi-asserted-by":"publisher","first-page":"947375","DOI":"10.3389\/fpubh.2022.947375","volume":"10","author":"ZM Ye","year":"2022","unstructured":"Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for american patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10:947375.","journal-title":"Front Public Health"},{"key":"1816_CR55","doi-asserted-by":"publisher","first-page":"107219","DOI":"10.1016\/j.lungcan.2023.107219","volume":"180","author":"A Tada","year":"2023","unstructured":"Tada A, Minami T, Kitai H, Higashiguchi Y, Tokuda M, Higashiyama T, Negi Y, Horio D, Nakajima Y, Otsuki T, et al. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation. Lung Cancer. 2023;180:107219.","journal-title":"Lung Cancer"},{"issue":"3","key":"1816_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-023-02292-3","volume":"28","author":"A Nakamura","year":"2023","unstructured":"Nakamura A, Hashimoto M, Kondo N, Matsumoto S, Kuroda A, Minami T, Kitajima K, Kuribayashi K, Kijima T, Hasegawa S. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol. 2023;28(3):409\u201315.","journal-title":"Int J Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01816-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T03:31:10Z","timestamp":1729740670000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01816-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01816-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with Declaration of Helsinki and approved by the Institutional Review Board (AVEN) (protocol number 2020\/0063362). Written consent was obtained from all living patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"114"}}